ResMed debuts a home apnea test

Article Excerpt

RESMED INC., $213.97, is a buy. The company’s (New York symbol RMD; TSINetwork Rating: Average)(www.resmed.com; Shares outstanding: 146.9 million; Market cap: $31.4 billion; Dividend yield: 1.0%) home sleep apnea test, NightOwl, is now available across the U.S. It’s an FDA-cleared home sleep apnea test designed to offer healthcare providers a simplified, accurate, and efficient way to diagnose obstructive sleep apnea from the comfort of an individual’s home. Sleep data is then sent remotely to a cloud-based diagnostic platform for physician analysis and review; that enables quick er interpretation of results and diagnosis. ResMed is still a buy. buy…